Australian biotech market watch 22/07/09
Wednesday, 22 July, 2009
The All Ordinaries has bounced up this week, pipping the 4,000 mark for the first time since mid-June, buoyed by optimistic mumblings from the US and Chinese markets along with indications the Australian market has touched bottom and is on its way up for a breath.
The health indices followed a similar pattern to the All Ords, at least until this morning, when they shed much of the gains made earlier in the week, dropping 59 points to 7,757.
After a turbulent couple of weeks, Cochlear (ASX:COH) gained ground through Monday and Tuesday, only to slip 1.3% in today's trading to $54.10.
Fisher & Paykel Healthcare (ASX:FPH) has continued to make gains, pushing its recent two month high to $2.48.
After it was announced that the competition watchdog is considering launching an investigation into pathology billing practices, both Primary Health Care (ASX:PRY) and Sonic Health Care (ASX:SHL) are down, by 3.4% and 3% respectively. This comes hot on the heels of Primary Health Care issuing 10 million new shares on Monday.
Ramsay Health Care (ASX:RHC), which had a strong week last week, shed 24c in today's trading to hit $10.61.
ResMed dropped sharply on Tuesday morning but has clawed its way back to close to Monday's close, sitting at $4.92 around 2.30pm, up 1.44% for the day.
Sigma Pharmaceuticals (ASX:SIP) has made steady gains since Monday morning, up 4.9% today to $1.29.
Ansell and CSL remain steady.
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
